Watkins Jonathan D, Smith Harry A, Hengist Aaron, Brunsgaard Lise Høj, Mikkelsen Ulla Ramer, Koumanov Francoise, Betts James A, Gonzalez Javier T
Centre for Nutrition, Exercise and Metabolism, Department for Health, University of Bath, Bath, UK.
Arla Foods Ingredients Group P/S, Viby J, Denmark.
Br J Nutr. 2021 Aug 9:1-9. doi: 10.1017/S000711452100297X.
A high dose of whey protein hydrolysate fed with milk minerals rich in calcium (Capolac®) results in enhanced glucagon-like peptide-1 (GLP-1) concentrations in lean individuals; however, the effect of different calcium doses ingested alongside protein is unknown. The present study assessed the dose response of calcium fed alongside 25 g whey protein hydrolysate on GLP-1 concentrations in individuals with overweight/obesity. Eighteen adults (mean ± sd: 8M/10F, 34 ± 18 years, 28·2 ± 2·9 kgm-2) completed four trials in a randomised, double-blind, crossover design. Participants consumed test solutions consisting of 25 g whey protein hydrolysate (CON), supplemented with 3179 mg (LOW), 6363 mg (MED) or 9547 mg (HIGH) Capolac® on different occasions, separated by at least 48 h. The calcium content of test solutions equated to 65, 892, 1719 and 2547 mg, respectively. Arterialised-venous blood was sampled over 180 min to determine plasma concentrations of GLP-1TOTAL, GLP-17-36amide, insulin, glucose, NEFA, and serum concentrations of calcium and albumin. Ad libitum energy intake was measured at 180 min. Time-averaged incremental AUC (iAUC) for GLP-1TOTAL (pmol·l-1·min-1) did not differ between CON (23 ± 4), LOW (25 ± 6), MED (24 ± 5) and HIGH (24 ± 6). Energy intake (kcal) did not differ between CON (940 ± 387), LOW (884 ± 345), MED (920 ± 334) and HIGH (973 ± 390). Co-ingestion of whey protein hydrolysate with Capolac® does not potentiate GLP-1 release in comparison with whey protein hydrolysate alone. The study was registered at clinical trials (NCT03819972).
高剂量乳清蛋白水解物与富含钙的乳矿物质(Capolac®)一起摄入,可使瘦人胰高血糖素样肽-1(GLP-1)浓度升高;然而,与蛋白质一起摄入不同剂量钙的效果尚不清楚。本研究评估了与25 g乳清蛋白水解物一起摄入钙对超重/肥胖个体GLP-1浓度的剂量反应。18名成年人(平均±标准差:8名男性/10名女性,34±18岁,28.2±2.9 kg/m²)以随机、双盲、交叉设计完成了四项试验。参与者在不同时间饮用由25 g乳清蛋白水解物(CON)组成的测试溶液,分别添加3179 mg(低剂量)、6363 mg(中剂量)或9547 mg(高剂量)的Capolac®,间隔至少48小时。测试溶液中的钙含量分别相当于65、892、1719和2547 mg。在长达180分钟的时间内采集动脉化静脉血,以测定血浆中总GLP-1、GLP-1 7-36酰胺、胰岛素、葡萄糖、非酯化脂肪酸的浓度,以及血清中钙和白蛋白的浓度。在180分钟时测量随意能量摄入量。总GLP-1(pmol·l⁻¹·min⁻¹)的时间平均增量AUC(iAUC)在CON组(23±4)、低剂量组(25±6)、中剂量组(24±5)和高剂量组(24±6)之间没有差异。能量摄入量(千卡)在CON组(940±387)、低剂量组(884±345)、中剂量组(920±334)和高剂量组(973±390)之间没有差异。与单独摄入乳清蛋白水解物相比,乳清蛋白水解物与Capolac®共同摄入不会增强GLP-1的释放。该研究已在临床试验注册(NCT03819972)。